Cartesian Therapeutics (RNAC) jumped over 30% on Tuesday after announcing a licensing deal to develop its CAR-T cell ...

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically ...

Approval paves the way for CTA313 clinical study in the United States for patients with systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitisBOSTON, June 09, 2026 ...

Key Points Interested in Caribou Biosciences, Inc.? Here are five stocks we like better. Vispa-cel, Caribou's off-the-shelf ...

Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.

At age 49, Jan Janisch-Hanzlik's multiple sclerosis was destroying her freedom to live the life she wanted. She gave up her active nursing job for a desk role. Frequent falls made her afraid to carry ...

A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single gene-regulating protein.

CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand could make it even more effective ...

In addition to scalability, another opportunity is presented by clinical feasibility and performance. For example, lymphodepletion conditioning, which is a must for ex vivo-engineered CAR-T cells, is ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies. However, its limitations remain evident. In ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...